Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5d/2a/05/5d2a05d6-9e8f-ebde-5b02-4e7f17c31d76/mza_720905515349598464.jpg/600x600bb.jpg

Foundation Fighting Blindness

238 episodes

1 week ago

The Foundation funded preclinical studies for the approach and launched Opus.

All content for Foundation Fighting Blindness is the property of Foundation Fighting Blindness and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The Foundation funded preclinical studies for the approach and launched Opus.

Science

https://i1.sndcdn.com/avatars-YaeofrSuCwcgCMse-dnoERw-original.jpg

Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

Foundation Fighting Blindness

4 minutes

4 months ago

Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

The expanded Phase 1/2/3 shortens time to potential FDA approval.